Treatment of Thoracic Outlet Syndrome (TOS) With Botox
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00444886 |
Recruitment Status :
Completed
First Posted : March 8, 2007
Last Update Posted : February 10, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is:
- To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.
- To assess the effect of BOTOX injection on numbness and tingling and quality of life.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Thoracic Outlet Syndrome | Drug: Botulinum Toxin Type A injection (BOTOX) | Phase 2 |
Background:
Thoracic Outlet Syndrome (TOS) is a symptom complex consisting of pain, paresthesias and often functional impairment caused by compression of the neurovascular supply to the upper limb. Impingement may occur at the interscalene triangle, and both anesthetic blockade and chemodenervation of the scalene muscles have been shown to temporarily improve symptoms of TOS in non-randomized controlled trials.
Objective:
To assess the effect of Botulinum Toxin Type A (BTX-A) injections into the scalene muscles on pain, paresthesias and function in subjects with TOS.
Hypothesis:
BTX-A injected into the anterior and middle scalene muscles will reduce the irritation on the neurovascular structures at the interscalene triangle in subjects with TOS. This will lead to reductions in pain and paresthesias, and improvements in function when compared with injection of placebo.
Intervention:
Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Treatment of Thoracic Outlet Syndrome With Botulinum Toxin Injection: A Double-Blind, Randomized Controlled Trial |
Study Start Date : | May 2007 |
Actual Primary Completion Date : | February 2011 |
Actual Study Completion Date : | February 2011 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.
|
Drug: Botulinum Toxin Type A injection (BOTOX)
Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program. |
Active Comparator: 2
To assess the effect of BOTOX injection on numbness and tingling and quality of life.
|
Drug: Botulinum Toxin Type A injection (BOTOX)
Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program. |
- Pain as measured on Visual Analog Scale (VAS) at 6 weeks, 3 months and 6 months post-intervention [ Time Frame: 6 monhts ]
- Paresthesias as measured on VAS [ Time Frame: 6 months ]
- Function as measured with Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, SF-36, number of days lost from work [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age at least 19 years
- Medically stable
- Able to give informed consent
- Meets criteria for clinical diagnosis of TOS
- Symptoms of TOS present for at least six months
- Have had EMG studies and a CT or MRI scan of the cervical spine
Exclusion Criteria:
- Prior treatment with BTX-A
- Allergy to BTX-A
- History of botulinum toxicity
- Prior scalenectomy
- Surgery for TOS planned within six months
- Use of blood thinners, i.e., warfarin; unfractionated or low molecular weight heparin
- History of Myasthenia Gravis, Eaton-Lambert Syndrome or Shy-Drager Syndrome
- Unable to complete follow-up assessments at 6 weeks, 3 months and 6 months
- Any abnormalities on EMG, CT or MRI studies suggesting an alternate diagnosis
- Pregnancy or planned pregnancy within six months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00444886
Canada, British Columbia | |
GF Strong Rehabilitation Centre | |
Vancouver, British Columbia, Canada, V5Z 2G9 |
Principal Investigator: | Andrew Travlos, MD | University of British Columbia |
Responsible Party: | Heather Finlayson, University of British Columbia |
ClinicalTrials.gov Identifier: | NCT00444886 |
Other Study ID Numbers: |
H06-03355 Data not known |
First Posted: | March 8, 2007 Key Record Dates |
Last Update Posted: | February 10, 2011 |
Last Verified: | February 2011 |
Thoracic Outlet Syndrome (TOS) Botulinum Toxin Botox Pain |
Nerve Compression Syndromes Thoracic Outlet Syndrome Syndrome Disease Pathologic Processes Vascular Diseases Cardiovascular Diseases Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases Botulinum Toxins |
Botulinum Toxins, Type A abobotulinumtoxinA Acetylcholine Release Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents |